

John M Lachin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2316927/publications.pdf>

Version: 2024-02-01

255
papers

64,943
citations

3930

88
h-index

750

250
g-index

278
all docs

278
docs citations

278
times ranked

43763
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. <i>New England Journal of Medicine</i> , 2002, 346, 393-403.	13.9	16,031
2	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 2117-2128.	13.9	8,841
3	Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2005, 353, 2643-2653.	13.9	4,433
4	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 323-334.	13.9	2,809
5	Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. <i>New England Journal of Medicine</i> , 2006, 355, 2427-2443.	13.9	2,714
6	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 232-242.	13.9	2,188
7	Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy. <i>New England Journal of Medicine</i> , 2000, 342, 381-389.	13.9	1,460
8	Effect of Weight Loss With Lifestyle Intervention on Risk of Diabetes. <i>Diabetes Care</i> , 2006, 29, 2102-2107.	4.3	1,050
9	Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function. <i>New England Journal of Medicine</i> , 2009, 361, 2143-2152.	13.9	900
10	Introduction to sample size determination and power analysis for clinical trials. <i>Contemporary Clinical Trials</i> , 1981, 2, 93-113.	2.0	897
11	Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2002, 346, 1685-1691.	13.9	793
12	Intensive Diabetes Therapy and Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2003, 348, 2294-2303.	13.9	761
13	Statistical Considerations in the Intent-to-Treat Principle. <i>Contemporary Clinical Trials</i> , 2000, 21, 167-189.	2.0	543
14	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018, 41, 356-363.	4.3	534
15	Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2011, 365, 2366-2376.	13.9	507
16	Rosiglitazone-Associated Fractures in Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 845-851.	4.3	498
17	Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention Program. <i>Diabetes Care</i> , 2007, 30, 2453-2457.	4.3	479
18	Achieving Weight and Activity Goals Among Diabetes Prevention Program Lifestyle Participants. <i>Obesity</i> , 2004, 12, 1426-1434.	4.0	470

#	ARTICLE	IF	CITATIONS
19	A Controlled Trial of Plasmapheresis Therapy in Severe Lupus Nephritis. <i>New England Journal of Medicine</i> , 1992, 326, 1373-1379.	13.9	459
20	Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited. <i>Diabetes</i> , 2008, 57, 995-1001.	0.3	432
21	Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 45.	3.8	369
22	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 119-129.	1.6	347
23	Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification. <i>Biometrics</i> , 1986, 42, 507.	0.8	343
24	Costs Associated With the Primary Prevention of Type 2 Diabetes Mellitus in the Diabetes Prevention Program. <i>Diabetes Care</i> , 2003, 26, 36-47.	4.3	322
25	Effect of Prior Intensive Insulin Treatment During the Diabetes Control and Complications Trial (DCCT) on Peripheral Neuropathy in Type 1 Diabetes During the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Diabetes Care</i> , 2010, 33, 1090-1096.	4.3	315
26	A Controlled Clinical Trial of Dichloroacetate for Treatment of Lactic Acidosis in Adults. <i>New England Journal of Medicine</i> , 1992, 327, 1564-1569.	13.9	312
27	Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients With Type 1 Diabetes Mellitus. <i>JAMA Ophthalmology</i> , 2008, 126, 1707.	2.6	301
28	Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria_{title}_{subtitle}_{An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort}_{title}_{Microalbuminuria Outcomes in Type 1 Diabetes}. <i>Archives of Internal Medicine</i> , 2011, 171, 412.	4.3	298
29	Properties of the urn randomization in clinical trials. <i>Contemporary Clinical Trials</i> , 1988, 9, 345-364.	2.0	277
30	Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus. <i>Circulation</i> , 2009, 119, 2886-2893.	1.6	271
31	Fall in C-Peptide During First 2 Years From Diagnosis. <i>Diabetes</i> , 2012, 61, 2066-2073.	0.3	270
32	Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC. <i>Diabetes</i> , 2015, 64, 631-642.	0.3	261
33	Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Care</i> , 2010, 33, 1536-1543.	4.3	257
34	Properties of permuted-block randomization in clinical trials. <i>Contemporary Clinical Trials</i> , 1988, 9, 327-344.	2.0	256
35	Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β -Cell Function in Therapeutic Trials in Type 1 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1966-1971.	4.3	250
36	The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes</i> , 2006, 55, 3556-3565.	0.3	238

#	ARTICLE	IF	CITATIONS
37	Randomization in clinical trials: Conclusions and recommendations. Contemporary Clinical Trials, 1988, 9, 365-374.	2.0	236
38	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology, the, 2019, 7, 128-139.	5.5	223
39	Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care, 2013, 36, 2254-2261.	4.3	217
40	A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 2002, 25, 1737-1743.	4.3	215
41	Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions. Diabetes, 2013, 62, 3976-3986.	0.3	215
42	Effects of Rosiglitazone, Glyburide, and Metformin on β -Cell Function and Insulin Sensitivity in ADOPT. Diabetes, 2011, 60, 1552-1560.	0.3	208
43	Evaluating the Role of Epigenetic Histone Modifications in the Metabolic Memory of Type 1 Diabetes. Diabetes, 2014, 63, 1748-1762.	0.3	208
44	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2016, 374, 1092-1094.	13.9	208
45	Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial. Diabetes, 2014, 63, 739-748.	0.3	201
46	The role of measurement reliability in clinical trials. Clinical Trials, 2004, 1, 553-566.	0.7	199
47	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME [®] trial. European Heart Journal, 2018, 39, 363-370.	1.0	199
48	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME [®] , Φ). Cardiovascular Diabetology, 2014, 13, 102.	2.7	198
49	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINagliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA [®]). Diabetes and Vascular Disease Research, 2015, 12, 164-174.	0.9	197
50	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 126.	3.0	196
51	Natural history and course of acquired lactic acidosis in adults. American Journal of Medicine, 1994, 97, 47-54.	0.6	194
52	Statistical properties of randomization in clinical trials. Contemporary Clinical Trials, 1988, 9, 289-311.	2.0	186
53	A review of methods for futility stopping based on conditional power. Statistics in Medicine, 2005, 24, 2747-2764.	0.8	186
54	Relationship of Glycated Albumin to Blood Glucose and HbA1c Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study. Diabetes, 2014, 63, 282-290.	0.3	186

#	ARTICLE	IF	CITATIONS
55	Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3002-11.	3.3	179
56	Fallacies of last observation carried forward analyses. Clinical Trials, 2016, 13, 161-168.	0.7	174
57	Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2014, 37, 39-43.	4.3	173
58	Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes. Diabetes, 2006, 55, 2357-2364.	0.3	169
59	Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 134-142.	1.8	164
60	The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatric Diabetes, 2009, 10, 97-104.	1.2	160
61	Properties of simple randomization in clinical trials. Contemporary Clinical Trials, 1988, 9, 312-326.	2.0	144
62	Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care, 2017, 40, 777-783.	4.3	141
63	Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials. Contemporary Clinical Trials, 1999, 20, 408-422.	2.0	140
64	Failure to Preserve β -Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New-Onset Type 1 Diabetes. Diabetes Care, 2010, 33, 826-832.	4.3	140
65	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. Diabetes and Vascular Disease Research, 2013, 10, 289-301.	0.9	132
66	Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. American Journal of Clinical Nutrition, 2009, 89, 518-524.	2.2	128
67	Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care, 2018, 41, 1696-1706.	4.3	127
68	Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data. Journal of the American Statistical Association, 1988, 83, 339-347.	1.8	119
69	Skin Advanced Glycation End Products Glucosepane and Methylglyoxal Hydroimidazolone Are Independently Associated With Long-term Microvascular Complication Progression of Type 1 Diabetes. Diabetes, 2015, 64, 266-278.	0.3	115
70	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β -Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care, 2018, 41, 1917-1925.	4.3	114
71	Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2019, 42, 875-882.	4.3	114
72	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke, 2017, 48, 1218-1225.	1.0	112

#	ARTICLE	IF	CITATIONS
73	Impact of Insulin and Metformin Versus Metformin Alone on β -Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1717-1725.	4.3	112
74	Progression of Carotid Artery Intima-Media Thickness During 12 Years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes</i> , 2011, 60, 607-613.	0.3	109
75	DCCT and EDIC Studies in Type 1 Diabetes: Lessons for Diabetic Neuropathy Regarding Metabolic Memory and Natural History. <i>Current Diabetes Reports</i> , 2010, 10, 276-282.	1.7	108
76	Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2017, 40, 1010-1016.	4.3	108
77	Pretreatment Biliary Lipid Composition in White Patients with Radiolucent Gallstones in the National Cooperative Gallstone Study. <i>Gastroenterology</i> , 1982, 83, 738-752.	0.6	107
78	Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes</i> , 2020, 69, 1000-1010.	0.3	106
79	Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. <i>Statistics in Medicine</i> , 1992, 11, 1151-1170.	0.8	105
80	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. <i>Diabetes Care</i> , 2018, 41, 1887-1894.	4.3	104
81	A Genome-Wide Association Study Identifies a Novel Major Locus for Glycemic Control in Type 1 Diabetes, as Measured by Both A1C and Glucose. <i>Diabetes</i> , 2010, 59, 539-549.	0.3	103
82	Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2017, 376, 1507-1516.	13.9	101
83	A Risk Score for Type 1 Diabetes Derived From Autoantibody-Positive Participants in the Diabetes Prevention Trial—Type 1. <i>Diabetes Care</i> , 2008, 31, 528-533.	4.3	98
84	Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2008, 168, 1867.	4.3	98
85	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1969-1977.	2.2	93
86	The use of response-adaptive designs in clinical trials. <i>Contemporary Clinical Trials</i> , 1993, 14, 471-484.	2.0	92
87	Type 1 Diabetes TrialNet—An International Collaborative Clinical Trials Network. <i>Annals of the New York Academy of Sciences</i> , 2008, 1150, 14-24.	1.8	92
88	Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes. <i>Diabetes</i> , 2009, 58, 2588-2595.	0.3	92
89	Effect of rituximab on human <i>in vivo</i> antibody immune responses. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1295-1302.e5.	1.5	91
90	Multiple Superoxide Dismutase 1/Splicing Factor Serine Alanine 15 Variants Are Associated With the Development and Progression of Diabetic Nephropathy. <i>Diabetes</i> , 2008, 57, 218-228.	0.3	89

#	ARTICLE	IF	CITATIONS
91	Intensive Diabetes Therapy and Ocular Surgery in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2015, 372, 1722-1733.	13.9	86
92	Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program. <i>Diabetes</i> , 2007, 56, 1153-1159.	0.3	84
93	National Cooperative Gallstone Study. <i>Gastroenterology</i> , 1982, 82, 638-646.	0.6	82
94	Levels of Oxidized LDL and Advanced Glycation End Products—Modified LDL in Circulating Immune Complexes Are Strongly Associated With Increased Levels of Carotid Intima-Media Thickness and Its Progression in Type 1 Diabetes. <i>Diabetes</i> , 2011, 60, 582-589.	0.3	82
95	Effect of Intensive Glycemic Therapy on Erectile Function in Men With Type 1 Diabetes. <i>Journal of Urology</i> , 2011, 185, 1828-1834.	0.2	80
96	Myocardial Structure, Function, and Scar in Patients With Type 1 Diabetes Mellitus. <i>Circulation</i> , 2011, 124, 1737-1746.	1.6	80
97	Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. <i>Biostatistics</i> , 2016, 17, 178-187.	0.9	77
98	Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2342-2350.	3.0	76
99	Risk Factors for Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 883-890.	4.3	76
100	Parametric survival models for interval-censored data with time-dependent covariates. <i>Biostatistics</i> , 2006, 7, 599-614.	0.9	72
101	Implementation of Group Sequential Logrank Tests in a Maximum Duration Trial. <i>Biometrics</i> , 1990, 46, 759.	0.8	69
102	The Effect of Intensive Diabetes Treatment on Resting Heart Rate in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Care</i> , 2007, 30, 2107-2112.	4.3	68
103	Increased T Cell Proliferative Responses to Islet Antigens Identify Clinical Responders to Anti-CD20 Monoclonal Antibody (Rituximab) Therapy in Type 1 Diabetes. <i>Journal of Immunology</i> , 2011, 187, 1998-2005.	0.4	65
104	Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1032-1040.	2.2	64
105	The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. <i>Diabetologia</i> , 2017, 60, 2084-2091.	2.9	62
106	Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2020, 43, 867-874.	4.3	61
107	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , 2017, 40, 1763-1770.	4.3	60
108	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , 2018, 41, 596-603.	4.3	59

#	ARTICLE	IF	CITATIONS
109	Sample Size Determinations for r x c Comparative Trials. <i>Biometrics</i> , 1977, 33, 315.	0.8	58
110	Power and sample size evaluation for the mcnemar test with application to matched case-control studies. <i>Statistics in Medicine</i> , 1992, 11, 1239-1251.	0.8	57
111	The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial. <i>Diabetes</i> , 2007, 56, 1913-1921.	0.3	57
112	Lack of Durable Improvements in β -Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1742-1751.	4.3	56
113	Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 436-445.	5.5	56
114	Circulating Vitamin D Metabolites and Kidney Disease in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4780-4788.	1.8	55
115	Depression as a symptom of alcoholism: Search for a phenomenon.. <i>Journal of Abnormal Psychology</i> , 1968, 73, 195-197.	2.0	55
116	DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes. <i>Nature Metabolism</i> , 2020, 2, 744-762.	5.1	53
117	Interim analyses with repeated measurements in a sequential clinical trial. <i>Biometrika</i> , 1990, 77, 359-364.	1.3	51
118	A Prospective Morphologic Evaluation of Hepatic Toxicity of Chenodeoxycholic Acid in Patients with Cholelithiasis: The National Cooperative Gallstone Study. <i>Hepatology</i> , 1982, 2, 187S-201S.	3.6	51
119	Sample size evaluation for a multiply matched case-control study using the score test from a conditional logistic (discrete Cox PH) regression model. <i>Statistics in Medicine</i> , 2008, 27, 2509-2523.	0.8	50
120	Determining Stability of Stored Samples Retrospectively: The Validation of Glycated Albumin. <i>Clinical Chemistry</i> , 2011, 57, 286-290.	1.5	50
121	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , 2017, 40, 164-170.	4.3	49
122	The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1341-1349.	2.3	47
123	Comparison of Urinary Albumin-Creatinine Ratio and Albumin Excretion Rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1235-1242.	2.2	46
124	The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 141-149.	1.2	46
125	Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2015, 14, 118.	2.7	46
126	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021, 8, 4517-4527.	1.4	46

#	ARTICLE	IF	CITATIONS
127	Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. <i>Atherosclerosis</i> , 2011, 214, 462-467.	0.4	43
128	Factors Affecting the Decline in Incidence of Diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). <i>Diabetes</i> , 2015, 64, 989-998.	0.3	43
129	Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 1284-1289.	4.3	42
130	Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	42
131	Group Sequential Distribution-Free Methods for the Analysis of Multivariate Observations. <i>Biometrics</i> , 1992, 48, 1033.	0.8	41
132	Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT). <i>Diabetes Care</i> , 2010, 33, 177-183.	4.3	40
133	Longitudinal Changes in Estimated and Measured GFR in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 810-818.	3.0	40
134	Link-Based Models for Survival Data with Interval and Continuous Time Censoring. <i>Biometrics</i> , 1997, 53, 1199.	0.8	39
135	Effects of Prior Intensive Versus Conventional Therapy and History of Glycemia on Cardiac Function in Type 1 Diabetes in the DCCT/EDIC. <i>Diabetes</i> , 2013, 62, 3561-3569.	0.3	38
136	Association of Cardiovascular Risk Factors and Myocardial Fibrosis With Early Cardiac Dysfunction in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Care</i> , 2017, 40, 405-411.	4.3	38
137	Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. <i>Statistics in Medicine</i> , 1986, 5, 73-83.	0.8	37
138	High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1416-1423.	0.4	37
139	Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 854-861.	2.2	37
140	Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC). <i>Diabetes Care</i> , 2021, 44, 2216-2224.	4.3	37
141	Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes. <i>PLoS ONE</i> , 2011, 6, e26471.	1.1	37
142	Haptoglobin Genotype and the Rate of Renal Function Decline in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes</i> , 2013, 62, 3218-3223.	0.3	36
143	Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 364-367.	1.2	35
144	Ultrastructural Evidence of Intrahepatic Cholestasis Before and After Chenodeoxycholic Acid Therapy in Patients with Cholelithiasis: The National Cooperative Gallstone Study. <i>Hepatology</i> , 2007, 3, 209-220.	3.6	32

#	ARTICLE	IF	CITATIONS
145	Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 657-664.	4.3	32
146	On Stepwise Discriminant Analyses Applied to Physiologic Data. <i>Psychophysiology</i> , 1974, 11, 703-709.	1.2	31
147	Circulating Vitamin D Metabolites and Subclinical Atherosclerosis in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2423-2429.	4.3	30
148	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 1599-1601.	1.6	28
149	Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data. <i>Journal of the American Statistical Association</i> , 1988, 83, 339.	1.8	28
150	Applications of the Wei-Lachin Multivariate One-Sided Test for Multiple Outcomes on Possibly Different Scales. <i>PLoS ONE</i> , 2014, 9, e108784.	1.1	27
151	Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. <i>Diabetes Care</i> , 2018, 41, 2495-2501.	4.3	27
152	Termination of a clinical trial with no treatment group difference: The Lupus Nephritis Collaborative Study. <i>Contemporary Clinical Trials</i> , 1992, 13, 62-79.	2.0	26
153	Gaps in the Glycation Gap Hypothesis. <i>Clinical Chemistry</i> , 2011, 57, 150-152.	1.5	26
154	The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 108-114.	1.2	26
155	What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 911-915.	1.2	26
156	Use of spending functions for occasional or continuous monitoring of data in clinical trials. <i>Statistics in Medicine</i> , 1993, 12, 2219-2231.	0.8	25
157	Application of the Wei-Lachin multivariate one-directional test to multiple event-time outcomes. <i>Clinical Trials</i> , 2015, 12, 627-633.	0.7	25
158	Power and sample size evaluation for the Cochran-Mantel-Haenszel mean score (Wilcoxon rank) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.8	24
159	Aortic Distensibility in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2380-2387.	4.3	23
160	Estimators and Tests in the Analysis of Multiple Nonindependent 2 X 2 Tables with Partially Missing Observations. <i>Biometrics</i> , 1988, 44, 513.	0.8	22
161	Sequential Monitoring of Survival Data with the Wilcoxon Statistic. <i>Biometrics</i> , 1995, 51, 1175.	0.8	21
162	Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit. <i>Clinical Trials</i> , 2009, 6, 565-573.	0.7	21

#	ARTICLE	IF	CITATIONS
163	Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients. <i>Journal of Diabetes Investigation</i> , 2022, 13, 125-133.	1.1	21
164	The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2225-2230.	4.3	21
165	Haptoglobin 2 nd genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1577-1584.	1.2	20
166	OGTT Glucose Response Curves, Insulin Sensitivity, and β -Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve β -Cell Function. <i>Diabetes Care</i> , 2021, 44, 817-825.	4.3	20
167	Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1499-1505.	4.3	20
168	Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2016, 15, 30.	2.7	19
169	An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. <i>Diabetes Care</i> , 2020, 43, 2478-2484.	4.3	19
170	Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 509-518.	5.5	19
171	Pilot Genome-Wide Association Search Identifies Potential Loci for Risk of Erectile Dysfunction in Type 1 Diabetes Using the DCCT/EDIC Study Cohort. <i>Journal of Urology</i> , 2012, 188, 514-520.	0.2	18
172	Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow-up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Journal of the American Heart Association</i> , 2016, 5, e002882.	1.6	18
173	Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Diabetes Care</i> , 2017, 40, 793-799.	4.3	18
174	Point: Intensive Glycemic Control and Mortality in ACCORD—A Chance Finding?. <i>Diabetes Care</i> , 2010, 33, 2719-2721.	4.3	17
175	Association of Baseline Characteristics With Insulin Sensitivity and β -Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. <i>Diabetes Care</i> , 2021, 44, 340-349.	4.3	16
176	Immune Complexes and the Risk of CVD in Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, 1853-1860.	0.3	15
177	Significance of Epicardial and Intrathoracic Adipose Tissue Volume among Type 1 Diabetes Patients in the DCCT/EDIC: A Pilot Study. <i>PLoS ONE</i> , 2016, 11, e0159958.	1.1	15
178	External monitoring of a data coordinating center: Experience of the national cooperative gallstone study. <i>Contemporary Clinical Trials</i> , 1987, 8, 1-11.	2.0	14
179	GROUP SEQUENTIAL MONITORING OF DISTRIBUTION-FREE ANALYSES OF REPEATED MEASURES. <i>Statistics in Medicine</i> , 1997, 16, 653-668.	0.8	14
180	Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study. <i>Diabetes Care</i> , 2022, 45, 659-665.	4.3	14

#	ARTICLE	IF	CITATIONS
181	Properties of randomization in clinical trials: Foreword. Contemporary Clinical Trials, 1988, 9, 287-288.	2.0	13
182	Over-ruling a group sequential boundary? a stopping rule versus a guideline. Statistics in Medicine, 2003, 22, 3347-3355.	0.8	13
183	Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata. Statistics in Medicine, 2013, 32, 4413-4425.	0.8	13
184	Mediation of the association of smoking and microvascular complications by glycemic control in type 1 diabetes. PLoS ONE, 2019, 14, e0210367.	1.1	13
185	Sequential Clinical Trials for Normal Variates Using Interval Composite Hypotheses. Biometrics, 1981, 37, 87.	0.8	12
186	Operating characteristics of sample size re-estimation with futility stopping based on conditional power. Statistics in Medicine, 2006, 25, 3348-3365.	0.8	12
187	A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. Pediatric Diabetes, 2011, 12, 85-90.	1.2	12
188	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. Hypertension, 2017, 70, 907-914.	1.3	12
189	Shape of the OGTT glucose response curve: relationship with β -cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. BMJ Open Diabetes Research and Care, 2021, 9, e002264.	1.2	12
190	Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC. BMJ Open Diabetes Research and Care, 2022, 10, e002667.	1.2	12
191	Central laboratory quality control in the national cooperative gallstone study. Contemporary Clinical Trials, 1983, 4, 101-123.	2.0	11
192	A Flexible Stochastic Curtailing Procedure for the Log-Rank Test. Contemporary Clinical Trials, 2000, 21, 428-439.	2.0	11
193	Application of robust estimating equations to the analysis of quantitative longitudinal data. Statistics in Medicine, 2001, 20, 3411-3428.	0.8	11
194	Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes: Response to McCarter et al.. Diabetes Care, 2005, 28, 233-233.	4.3	11
195	Nonparametric Statistical Analysis. JAMA - Journal of the American Medical Association, 2020, 323, 2080.	3.8	11
196	Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. PLoS ONE, 2021, 16, e0257154.	1.1	11
197	Conflicts of interest in data monitoring of industry versus publicly financed clinical trials. Statistics in Medicine, 2004, 23, 1519-1521.	0.8	10
198	On a Stepwise Procedure for Two Population Bayes Decision Rules Using Discrete Variables. Biometrics, 1973, 29, 551.	0.8	9

#	ARTICLE	IF	CITATIONS
199	The National Cooperative Gallstone Study and current management of cholesterol cholelithiasis—Two views. <i>Gastroenterology</i> , 1983, 84, 644-648.	0.6	9
200	Validity of Self-Report in Type 1 Diabetic Subjects for Laser Treatment of Retinopathy. <i>Ophthalmology</i> , 2013, 120, 2580-2586.	2.5	9
201	Biomarkers of tubulointerstitial damage and function in type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000461.	1.2	9
202	Association of Habitual Daily Physical Activity With Glucose Tolerance and β -Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. <i>Diabetes Care</i> , 2019, 42, 1521-1529.	4.3	9
203	Moderation of the effect of glycemia on the risk of cardiovascular disease in type 1 diabetes: The DCCT/EDIC study. <i>Diabetes Research and Clinical Practice</i> , 2021, 171, 108591.	1.1	9
204	Hyperglucagonemia Does Not Explain the β -Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. <i>Diabetes Care</i> , 2021, 44, 1961-1969.	4.3	9
205	Optimal screening schedules for disease progression with application to diabetic retinopathy. <i>Biostatistics</i> , 2018, 19, 1-13.	0.9	9
206	Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2405-e2416.	1.8	9
207	Distribution-Free Marginal Analysis of Repeated Measures. <i>Drug Information Journal</i> , 1996, 30, 1017-1028.	0.5	8
208	Relation Between Carotid Intima—Media Thickness and Left Ventricular Mass in Type 1 Diabetes Mellitus (from the Epidemiology of Diabetes Interventions and Complications [EDIC] Study). <i>American Journal of Cardiology</i> , 2012, 110, 1534-1540.	0.7	8
209	Stratified-adjusted versus unstratified assessment of sample size and power for analyses of proportions. <i>Cancer Treatment and Research</i> , 1995, 75, 203-223.	0.2	8
210	Coronary Artery Disease Events and Carotid Intima—Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort. <i>Journal of the American Heart Association</i> , 2021, 10, e022922.	1.6	8
211	The Society for Clinical Trials supports United States legislation mandating trials registration. <i>Clinical Trials</i> , 2004, 1, 417-420.	0.7	7
212	Maximum information designs. <i>Clinical Trials</i> , 2005, 2, 453-464.	0.7	7
213	Power of the Mantel—Haenszel and other tests for discrete or grouped time—event data under a chained binomial model. <i>Statistics in Medicine</i> , 2013, 32, 220-229.	0.8	7
214	Withdrawal of medications leads to worsening of <sc>OGTT</sc> parameters in youth with impaired glucose tolerance or <sc>recently—diagnosed</sc> type 2 diabetes. <i>Pediatric Diabetes</i> , 2020, 21, 1437-1446.	1.2	7
215	Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2022, 45, 1779-1787.	4.3	7
216	Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	5

#	ARTICLE	IF	CITATIONS
217	Risk Factors for Hearing Impairment in Type 1 Diabetes. <i>Endocrine Practice</i> , 2019, 25, 1243-1254.	1.1	5
218	Association of glycemia with insulin sensitivity and β -cell function in adults with early type 2 diabetes on metformin alone. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107912.	1.2	5
219	Phasic Heart Rate Responses: Different Patterns in Black and in White Newborns. <i>Psychosomatic Medicine</i> , 1975, 37, 326-332.	1.3	4
220	Martingales without tears. <i>Lifetime Data Analysis</i> , 1995, 1, 361-375.	0.4	4
221	Refractive Error and Retinopathy Outcomes in Type 1 Diabetes. <i>Ophthalmology</i> , 2021, 128, 554-560.	2.5	4
222	Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2021, 44, 1309-1316.	4.3	4
223	Effects of dose relative to body weight in the national cooperative gallstone study: A fixed-dose trial. <i>Contemporary Clinical Trials</i> , 1983, 4, 125-131.	2.0	3
224	Major issues in the organization and implementation of the national cooperative Gallstone Study (NCGS). <i>Contemporary Clinical Trials</i> , 1984, 5, 1-12.	2.0	3
225	Nonparametric test of stochastic ordering for multiple longitudinal measures. <i>Journal of Biopharmaceutical Statistics</i> , 1995, 5, 235-243.	0.4	3
226	Corrections for Bias in Maximum Likelihood Parameter Estimates Due to Nuisance Parameters. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2003, 32, 619-639.	0.6	3
227	A composite design for transition from a preliminary to a full-scale study. <i>Statistics in Medicine</i> , 2007, 26, 5014-5032.	0.8	3
228	Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. <i>Diabetes Care</i> 2017;40:655-662. <i>Diabetes Care</i> , 2018, 41, e64-e64.	4.3	3
229	Properties of composite time to first event versus joint marginal analyses of multiple outcomes. <i>Statistics in Medicine</i> , 2018, 37, 3918-3930.	0.8	3
230	Worst-Rank Score Methods—A Nonparametric Approach to Informatively Missing Data. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1670.	3.8	3
231	Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. <i>Diabetes</i> 2020;69:291-299. <i>Diabetes</i> , 2020, 69, e7-e8.	0.3	3
232	Remembrances of Max Halperin. <i>Statistics in Medicine</i> , 1990, 9, 863-870.	0.8	2
233	Probabilistic measures of cost-effectiveness. <i>Statistics in Medicine</i> , 2016, 35, 3976-3986.	0.8	2
234	Refining Measurement of Hemoglobin A1c. <i>Clinical Chemistry</i> , 2017, 63, 1433-1435.	1.5	2

#	ARTICLE	IF	CITATIONS
235	Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> 2017;40:777-783. <i>Diabetes Care</i> , 2017, 40, e165-e166.	4.3	2
236	Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. <i>Diabetes</i> , 2020, 69, 2440-2445.	0.3	2
237	Models to Assess the Association of a Semiquantitative Exposure With Outcomes. <i>American Journal of Epidemiology</i> , 2020, 189, 1573-1582.	1.6	2
238	Severe hypoglycaemia in Diabetes Control and Complications Trial. <i>Lancet</i> , The, 1994, 343, 1097-1098.	6.3	1
239	Group sequential large sample T ₂ -like tests for multivariate observations. <i>Statistics in Medicine</i> , 2003, 22, 3357-3368.	0.8	1
240	Methods for a longitudinal quantitative outcome with a multivariate Gaussian distribution multi-dimensionally censored by therapeutic intervention. <i>Statistics in Medicine</i> , 2014, 33, 1288-1306.	0.8	1
241	Data sharing is desirable, but benefits should not be exaggerated. <i>BMJ</i> , The, 2015, 351, h5508.	3.0	1
242	Closed testing using surrogate hypotheses with restricted alternatives. <i>PLoS ONE</i> , 2019, 14, e0219520.	1.1	1
243	Closed testing of each group versus the others combined in a multiple group analysis. <i>Clinical Trials</i> , 2020, 17, 77-86.	0.7	1
244	Identifying Change Points in a Covariate Effect on Time-to-Event Analysis with Reduced Isotonic Regression. <i>PLoS ONE</i> , 2014, 9, e113948.	1.1	1
245	Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 585-593.	4.3	1
246	Left Ventricular Structure, Tissue Composition, and Aortic Distensibility in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications. <i>American Journal of Cardiology</i> , 2022, 174, 158-165.	0.7	1
247	Permutation tests following restricted randomization procedures. <i>Contemporary Clinical Trials</i> , 1990, 11, 150-152.	2.0	0
248	Relationship of myocardial scar with cardiovascular disease risk factors in the diabetes control and complications trial (DCCT)/epidemiology of diabetes interventions and complications (EDIC) study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2010, 12, .	1.6	0
249	Reminiscences of Jerry Cornfield. <i>Clinical Trials</i> , 2013, 10, 337-339.	0.7	0
250	University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (afternoon panel session). <i>Clinical Trials</i> , 2018, 15, 366-385.	0.7	0
251	Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> 2019;42:657-664. <i>Diabetes Care</i> , 2019, 42, e137-e137.	4.3	0
252	The minimum intensity of a mixed exposure that increases the risk of an outcome. <i>Statistics in Medicine</i> , 2020, 39, 4016-4024.	0.8	0

#	ARTICLE	IF	CITATIONS
253	Cost-efficient clinical studies with continuous time survival outcomes. <i>Statistics in Medicine</i> , 2021, 40, 3682-3694.	0.8	0
254	Early Termination of the Diabetes Control and Complications Trial. , 2006, , 93-108.		0
255	The Department of Statistics at The George Washington University. , 2012, , 65-76.		0